Navigation Links
MIGENIX releases CEO message #22
Date:2/15/2008

VANCOUVER and San Diego, CA, Feb. 15 /PRNewswire-FirstCall/ - MIGENIX Inc. (TSX: MGI; OTC: MGIFF), a clinical-stage developer of drugs for infectious diseases, has issued its 22nd CEO Message from Jim DeMesa, MD, President & CEO. Today's CEO Message provides a discussion of the company's expected progress in 2008 and into 2009, including:

Omigard (prevention of catheter-related infections):

- Phase III results in H2/08

- NDA submission in H1/09

- Rest of world partnership

Celgosivir (hepatitis C virus):

- Phase II viral kinetics study results (including 600mg) in Q3/08

- Partnership

CLS001 (rosacea and other dermatologic conditions):

- Enter Phase III clinical development

MX-2401 (serious bacterial infections):

- Further advancement through preclinical development (clinicals

could begin in 2009)

To obtain a copy of the complete CEO Message, please visit the MIGENIX web site at http://www.migenix.com or contact Investor Relations at 1-800-665-1968, Extension 233 (also available on SEDAR and EDGAR).

About MIGENIX

MIGENIX is committed to advancing therapy, improving health, and enriching life by developing and commercializing drugs primarily in the area of infectious diseases. The Company's clinical programs include drug candidates for the treatment of chronic hepatitis C infections (Phase II and preclinical), the prevention of catheter-related infections (Phase III) and the treatment of dermatological diseases (Phase II). MIGENIX is headquartered in Vancouver, British Columbia, Canada with US operations in San Diego, California. Additional information can be found at http://www.migenix.com.

"Jim DeMesa"

James M. DeMesa, M.D.

President & CEO

FORWARD-LOOKING STATEMENTS

This news rel
'/>"/>

SOURCE MIGENIX Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. MIGENIX to Add 600mg Daily Celgosivir Dose to Phase II Viral Kinetics Study
2. MIGENIX Reports Second Quarter Fiscal Year 2008 Financial Results
3. MIGENIX Second Fiscal Quarter 2008 Financial Results Conference Call & Webcast Notification
4. MIGENIX to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
5. MIGENIX Reports First Quarter Fiscal Year 2008 Financial Results
6. MIGENIX to Present Positive Celgosivir Viral Resistance Data at International HCV Meeting
7. MIGENIX First Fiscal Quarter 2008 Financial Results Conference Call & Webcast Notification
8. National Nanotechnology Initiative releases its fiscal year 2009 budget and highlights
9. CellCyte Genetics Corp. Continues to Move Its Technology Forward in Light of Plaintiff Law Firm Press Releases
10. Intrasphere Technologies Releases PharmaCM Submissions Management and Authoring Module Powered by Microsoft Office SharePoint Server 2007
11. Techne Corporation Releases Unaudited Second Quarter Results for Fiscal Year 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... Boston, MA (PRWEB) November 26, 2014 ... and collaboration company is proud to announce that Darren ... Development and Sales. Darren will drive the ... and positive customer experience. , Darren brings ... He has held key roles in channel operations, from ...
(Date:11/26/2014)... November 26, 2014 2014 Deep ... an in-depth research report on the Global Palmitic ... introduces Palmitic Acid, basic information, including definition, classification, ... and news analysis, etc. , For international ... Palmitic Acid market in China and other ...
(Date:11/26/2014)... 2014 Bio-Techne Corporation (NASDAQ: TECH ... Gavin to serve in a newly created position ... Mr. Gavin will be responsible for managing the operations ... ProteinSimple business acquired in July 2014 and the recently ... California -based ProteinSimple develops and commercializes proprietary systems ...
(Date:11/26/2014)... 25, 2014  Roka Bioscience, Inc. (NASDAQ: ROKA ... solutions for the detection of foodborne pathogens, today announced that ... Jaffray  26 th Annual Healthcare Conference on December 2, ... The New York Palace in New York, NY ... concerning the Company, its operations, strategies and prospects may be ...
Breaking Biology Technology:SoundConnect Appoints Director of Channel Development & Sales 2Palmitic Acid Industry Global 2014 Analysis & 2020 Forecasts on Market data, Statics, Development Now at ReportsnReports.com 2Palmitic Acid Industry Global 2014 Analysis & 2020 Forecasts on Market data, Statics, Development Now at ReportsnReports.com 3Bio?Techne Announces Appointment Of Robert Gavin As Leader Of New Protein Platforms Division 2Bio?Techne Announces Appointment Of Robert Gavin As Leader Of New Protein Platforms Division 3Roka Bioscience to Present at the Piper Jaffray Healthcare Conference 2
... funded training programmes in biotechnology and biosafety warns ... unprepared to effectively manage and monitor the use ... to serious biosafety threats. , The report, from ... says training and management deficiencies in most countries ...
... North Carolina State University have created a substance far ... these properties under extremely high temperatures opening the ... as engine components that are exposed to high stress ... up of nanoscale crystals is far stronger and harder ...
... 27 (Nasdaq: WHRT, TSX:,WHT) -- World Heart ... 2008, it had received a letter from the ... Company,s request to appeal the NASDAQ Listing,Qualification Staff ... NASDAQ Stock Market. Accordingly, the delisting action,referenced in ...
Cached Biology Technology:Most developing countries ill-equipped to ensure global biosafety: UN University 2Most developing countries ill-equipped to ensure global biosafety: UN University 3WorldHeart Announces Delisting Appeal Received and Will be Considered at Hearing July 10, 2008 2
(Date:11/6/2014)... 6, 2014 - Insilico Medicine, Inc, a Baltimore-based ... age related diseases announced a research collaboration with ... Champions Oncology, Inc (OTC: CSBR). , "There are ... medicine, but Champions Oncology,s TumorGraft technology is unique ... chemotherapy regimen experimentally generating vast amounts of valuable ...
(Date:11/5/2014)... in their ability to identify scents and odors. ... perceptual evaluation of odors, with women outperforming men on ... differences in olfactory detection may play a role in ... perception of smell, which is naturally linked to associated ... suggested to be cognitive or emotional, rather than perceptual. ...
(Date:11/4/2014)... Temple University School of Medicine announced today that ... initiative funded by the Bill & Melinda Gates ... Obstetrics, Gynecology and Reproductive Sciences; and Vice Chair ... School of Medicine will pursue an innovative global ... Biomarkers to Assess Fetal Neurodevelopment.", Grand Challenges Explorations ...
Breaking Biology News(10 mins):Insilico Medicine, Inc announces research collaboration with Champions Oncology, Inc 2The female nose always knows: Do women have more olfactory neurons? 2Temple University School of Medicine receives Grand Challenges Explorations grant 2
... Energy crop company Ceres, Inc. and the Texas Agricultural ... Oct. 1 that they have entered into an exclusive, ... sorghum. These plants are not designed to produce ... raw material for a new generation of biofuels made ...
... Why a pathogen is a pathogen may be answered as ... that spawns the worst cereal grains disease known and also ... The fungus, which is especially destructive to wheat and barley, ... U.S. crops over the past 10 years. The scientists who ...
... Imaging and Bioengineering (NIBIB), part of the National ... of more than $12 million in grants to ... technologies to advance health care. The ... groundbreaking technologies: disposable microchips for the diagnosis ...
Cached Biology News:Ceres and Texas A&M to develop and market high-biomass sorghum for biofuels 2Fungus genome yielding answers to protect grains, people and animals 2Fungus genome yielding answers to protect grains, people and animals 3NIBIB invests in quantum research 2NIBIB invests in quantum research 3
Mouse IL-31 RA Biotinylated Affinity Purified PAb...
Sf21 cells derived from Spodoptera frugiperda ovarian cells are recommended for high-level production of recombinant proteins. Higher expression levels of some proteins are seen due to the larger ce...
... kit consists of universal lysis buffer, PCR ... for 100 25 l volume PCR reactions. ... Gram negative or positive rod and coccus ... Bacillus Cereus, Staphylococcus Aureus, Streptococcus Agalactiae, and ...
...
Biology Products: